The MarketWatch News Department was not involved in the creation of this content.
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference
50% of patients suffering from multiple sclerosis have one of the progressive forms of the disease, for which there is no satisfactory treatment to date
Masitinib, a tyrosine kinase inhibitor developed by AB Science, provides the first clinical evidence that targeting the innate immune system is an effective strategy for the treatment of progressive forms of multiple sclerosis.
AB Science SA (Euronext – FR0010557264 – AB), a pharmaceutical company specialized on the research, development and commercialization of protein kinase inhibitors (PKIs), announced today that it has presented the world’s first key results from its Phase 2B/3 study (AB07002) evaluating its lead product, masitinib, in both progressive forms of multiple sclerosis1 during the 8th Joint Meeting of